Company Filing History:
Years Active: 1988-1996
Title: Dan Shochat: Pioneering Radiolabeling Innovations in New Jersey
Introduction
Dan Shochat is an innovative inventor based in Maplewood, New Jersey. With an impressive portfolio of three patents, he has made significant contributions to the field of radiolabeling in protein chemistry. His work focuses on methods that enhance the stability and effectiveness of radiolabeled proteins, which can have vital applications in biomedical research and therapies.
Latest Patents
Dan’s latest patents include two notable methods for radiolabeling protein fragments. The first patent, titled "Method for Radiolabeling Antibody Fragments," describes a process where a protein containing at least one pendant sulfhydryl group is directly radiolabeled with a radiometal that binds tightly to these groups. This innovation utilizes endogenous ligands from the protein and may include an exogenous ligand to further stabilize the chelate. The second patent, "Method for Radiolabeling Proteins," employs a similar approach, reinforcing the utility and versatility of his techniques in molecular imaging and therapy.
Career Highlights
Dan Shochat is currently employed at Immunomedics, Inc., a leading biotechnology company known for its advancements in antibody-drug conjugates. His role at this esteemed organization allows him to apply his expertise in radiolabeling to further the company’s mission of developing targeted therapies for cancer treatment.
Collaborations
Throughout his career, Dan has collaborated with notable individuals, including coworkers Hans J. Hansen and Robert Sundoro Wu. These professional relationships contribute to a dynamic working environment, fostering innovation and collaborative problem-solving in scientific research.
Conclusion
Dan Shochat's work in the field of protein radiolabeling marks a significant advancement in the intersection of chemistry and medicine. His patents provide a strong foundation for future innovations that could revolutionize the way therapies are developed. As he continues to work at Immunomedics, Inc., the impact of his contributions will surely resonate in the biomedical community, paving the way for new treatments and better patient outcomes.